Changing concepts in the pathological basis of soft tissue and bone sarcoma treatment

European Journal of Cancer

Volumn 40, Issue 11, 2004, Pages 1644-1654

  Hogendoorn, Pancras C W ^a   Collin, Françoise ^b   Daugaard, Søren ^c   Dei Tos, A Paolo ^d   Fisher, Cyril ^e   Schneider, Ulrike ^f   Sciot, Raf ^g  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRE GEORGES FRANÇOIS LECLERC   (France)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d TREVISO REGIONAL HOSPITAL   (Italy)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f Section of Pathology   (Germany)

^g UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Classification; Clinical trials; Genetics; Pathology; Soft tissue tumours

Indexed keywords

CD99 ANTIGEN; GEFITINIB; GLIAL FIBRILLARY ACIDIC PROTEIN; IMATINIB; MYOGENIN; NEURON SPECIFIC ENOLASE; PROTEIN S 100; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR; TRASTUZUMAB; WT1 PROTEIN;

ADIPOCYTE; ANGIOMYOLIPOMA; CANCER CLASSIFICATION; CANCER GRADING; CELL DIFFERENTIATION; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG TARGETING; ENDOTHELIUM; EPITHELIUM; FIBROHISTIOCYTOMA; FLUORESCENCE IN SITU HYBRIDIZATION; FROZEN SECTION; GENE AMPLIFICATION; GENETIC ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; LABORATORY; LEIOMYOMATOSIS; LIPOSARCOMA; LYMPHANGIOMA; MELANOMA; MESENCHYMOMA; MORPHOLOGY; MUSCLE TUMOR; MYOFIBROBLAST; MYXOSARCOMA; NERVE SHEATH TUMOR; OSTEOSARCOMA; PATHOGENESIS; PERICYTE; PLEOMORPHIC ADENOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TUMOR BIOPSY; TUMOR DIFFERENTIATION; VASCULAR TUMOR; WORLD HEALTH ORGANIZATION;

EID: 3142647035     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.04.004     Document Type: Article

References (52)

1. Hogendoorn P.C.W. Pathology of soft tissue sarcomas with emphasis on molecular diagnostic techniques. Eur. J. Cancer. 2003;S205-S210
2. Fletcher CDM, Unnikk, Mertens F, (Eds.), World Health Organization Classification of Tumours. Pathology and genetics of tumours of soft tissue and bone; IARC Press, Lyon 2002
3. Weiss S.W., Sobin L.H. International histological classification of tumours. Histological typing of soft tissue tumours. 1994;World Health Organisation
4. Trojani M., Contesso G., Coindre J.M., Rouesse J., Bui N.B., De Mascarel A., et al. Soft tissue sarcomas of adults study of pathological prognostic variables and definition of a histopathological grading system. Int. J. Cancer. 33:1984;37-42
5. Guillou L., Coindre J.M., Bonichon F., Nguyen B.B., Terrier P., Collin F., et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J. Clin. Oncol. 15:1997;350-362
6. Kilpatrick S.E. Histologic prognostication in soft tissue sarcomas: grading versus subtyping or both? A comprehensive review of the literature with proposed practical guidelines. Ann. Diagn. Pathol. 3:1999;48-61
7. Coindre J.M., Terrier P., Guillou L., Le D.V., Collin F., Ranchere D., et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 91:2001;1914-1926
8. Coindre J.M. Immunohistochemistry in the diagnosis of soft tissue tumours. Histopathology. 43:2003;1-16
9. Fletcher C.D., Gustafson P., Rydholm A., Willen H., Akerman M. Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J. Clin. Oncol. 19:2001;3045-3050
10. Watanabe K., Kusakabe T., Hoshi N., Saito A., Suzuki T. h-Caldesmon in leiomyosarcoma and tumors with smooth muscle cell-like differentiation: its specific expression in the smooth muscle cell tumor. Hum. Pathol. 30:1999;392-396
11. Kumar S., Perlman E., Harris C.A., Raffeld M., Tsokos M. Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin-embedded tissues. Mod. Pathol. 13:2000;988-993
12. Miettinen M., Fanburg-Smith J.C., Virolainen M., Shmookler B.M., Fetsch J.F. Epithelioid sarcoma: an immunohistochemical analysis of 112 classical and variant cases and a discussion of the differential diagnosis. Hum. Pathol. 30:1999;934-942
13. van de R.M., Barr F.G., Xiong Q.B., Hedges M., Shipley J., Fisher C. Poorly differentiated synovial sarcoma: an analysis of clinical, pathologic and molecular genetic features. Am. J. Surg. Pathol. 23:1999;106-112
14. Hazelbag H.M., Mooi W.J., Fleuren G.J., Hogendoorn P.C.W. Chain-specific keratin profile of epithelioid soft-tissue sarcomas: an immunohistochemical study on synovial and epithelioid sarcoma. Appl. Immunohistochem. 4:1996;176-183
15. Fletcher C.D.M., Beham A., Bekir S., Clarke A.M., Marley N.J. Epithelioid angiosarcoma of deep soft tissue: a distinctive tumor readily mistaken for an epithelial neoplasm. Am. J. Surg. Pathol. 15:1991;915-924
16. Arber D.A., Kandalaft P.L., Mehta P., Battifora H. Vimentin-negative epithelioid sarcoma: the value of an immunohistochemical panel that includes CD34. Am. J. Surg. Pathol. 17:1993;302-307
17. Folpe A.L., Chand E.M., Goldblum J.R., Weiss S.W. Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics. Am. J. Surg. Pathol. 25:2001;1061-1066
18. Rossi S., Orvieto E., Furlanetto A., Laurino L., Ninfo V., Dei Tos A.P. The utility of the immunohistochemical detection of Fli-1 expression in round cell and vascular neoplasm using a monoclonal antibody. Mod. Pathol. 2003
19. Folpe A.L., Hill C.E., Parham D.M., O'Shea P.A., Weiss S.W. Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor. Am. J. Surg. Pathol. 24:2000;1657-1662
20. Courville P., Simon F., Le Pessot F., Tallet Y., Debab Y., Metayer J. [Detection of HHV8 latent nuclear antigen by immunohistochemistry. A new tool for differentiating Kaposi's sarcoma from its mimics]. Ann. Pathol. 22:2002;267-276
21. Ambros I.M., Ambros P.F., Strehl S., Kovar H., Gadner H., Salzer-Kuntschik M. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors: evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer. 67:1991;1886-1893
22. Nicholson S.A., McDermott M.B., Swanson P.E., Wick M.R. CD99 and cytokeratin-20 in small-cell and basaloid tumors of the skin. Appl. Immunohistochem. Mol. Morphol. 8:2000;37-41
23. Granter S.R., Renshaw A.A., Fletcher C.D.M., Bhan A.K., Rosenberg A.E. CD99 reactivity in mesenchymal chondrosarcoma. Hum. Pathol. 27:1996;1273-1276
24. Dei Tos A.P. The reappraisal of gastrointestinal stromal tumors: from Stout to the KIT revolution. Virchows Arch. 442:2003;421-428
25. Graadt van Roggen J.F., Van Velthuysen M.L.F., Hogendoorn P.C.W. The histopathological differential diagnosis of gastrointestinal stromal tumours. J. Clin. Pathol. 2001;96-103
26. Hornick J.L., Fletcher C.D. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am. J. Clin. Pathol. 117:2002;188-193
27. Sturtz C.L., Dabbs D.J. Angiomyolipomas: the nature and expression of the HMB45 antigen. Mod. Pathol. 7:1994;842-845
28. Hill D.A., Pfeifer J.D., Marley E.F., Dehner L.P., Humphrey P.A., Zhu X., et al. WT1 staining reliably differentiates desmoplastic small round cell tumor from Ewing sarcoma/primitive neuroectodermal tumor. An immunohistochemical and molecular diagnostic study. Am. J. Clin. Pathol. 114:2000;345-353
29. Ordonez N.G. Desmoplastic small round cell tumor: II: an ultrastructural and immunohistochemical study with emphasis on new immunohistochemical markers. Am. J. Surg. Pathol. 22:1998;1314-1327
30. Argani P., Lal P., Hutchinson B., Lui M.Y., Reuter V.E., Ladanyi M. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am. J. Surg. Pathol. 27:2003;750-761
31. Dei Tos A.P., Doglioni C., Piccinin S., Sciot R., Furlanetto A., Boiocchi M., et al. Coordinated expression and amplification of the MDM2, CDK4 and HMGI-C genes in atypical lipomatous tumours. J. Pathol. 190:2000;531-536
32. Coindre J.M., Mariani O., Chibon F., Mairal A., Saint Aubain S.N., Favre-Guillevin E., et al. Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. Mod. Pathol. 16:2003;256-262
33. Dei Tos A.P., Maestro R., Doglioni C., Gasparotto D., Boiocchi M., Laurino L., et al. Ultraviolet-induced p53 mutations in atypical fibroxanthoma. Am. J. Pathol. 145:1994;11-17
34. Graadt van Roggen J.F., Bovee J.V.M.G., Morreau J., Hogendoorn P.C.W. Diagnostic and prognostic implications of the unfolding molecular biology of bone and soft tissue tumours. J. Clin. Pathol. 52:1999;481-489
35. Verweij J., Van Oosterom A., Blay J.Y., Judson I., Rodenhuis S., van der G.W., et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur. J. Cancer. 39:2003;2006-2011
36. Onda M., Matsuda S., Higaki S., Iijima T., Fukushima J., Yokokura A., et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer. 77:1996;71-78
37. Gorlick R., Huvos A.G., Heller G., Aledo A., Beardsley G.P., Healey J.H., et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J. Clin. Oncol. 17:1999;2781-2788
38. Akatsuka T., Wada T., Kokai Y., Sawada N., Yamawaki S., Ishii S. Loss of ErbB2 expression in pulmonary metastatic lesions in osteosarcoma. Oncology. 60:2001;361-366
39. Akatsuka T., Wada T., Kokai Y., Kawaguchi S., Isu K., Yamashiro K., et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer. 94:2002;1397-1404
40. Maitra A., Wanzer D., Weinberg A.G., Ashfaq R. Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer. 92:2001;677-683
41. Thomas D.G., Giordano T.J., Sanders D., Biermann J.S., Baker L. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin. Cancer Res. 8:2002;788-793
42. Anninga J.K., Van de Vijver M.J., Cleton-Jansen A.M., Kristel P.M.P., Taminiau A.H.M., Nooij M., et al. Overexpression of the Her-2 oncogene does not play a role in high-grade osteosarcomas. Eur. J. Cancer. 40:2004;963-970
43. Kilpatrick S.E., Geisinger K.R., King T.S., Sciarrotta J., Ward W.G., Gold S.H., et al. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod. Pathol. 14:2001;1277-1283
44. Nielsen T.O., West R.B., Linn S.C., Alter O., Knowling M.A., O'Connell J.X., et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet. 359:2002;1301-1307
45. Nielsen T.O., Hsu F.D., O'Connell J.X., Gilks C.B., Sorensen P.H., Linn S., et al. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am. J. Pathol. 163:2003;1449-1456
46. van de R.M., Rubin B.P. Gene expression studies on soft tissue tumors. Am. J. Pathol. 161:2002;1531-1534
47. Nowak A.K., Byrne M.J., Williamson R., Ryan G., Segal A., Fielding D., et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br. J. Cancer. 87:2002;491-496
48. Gourley C., Al Nafussi A., Abdulkader M., Smyth J.F., Gabra H. Malignant mixed mesodermal tumours: biology and clinical aspects. Eur. J. Cancer. 38:2002;1437-1446
49. Werner M., Chott A., Fabiano A., Battifora H. Effect of formalin tissue fixation and processing on immunohistochemistry. Am. J. Surg. Pathol. 24:2000;1016-1019
50. Kononen J., Bubendorf L., Kallioniemi A., Barlund M., Schraml P., Leighton S., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 4:1998;844-847
51. Hoos A., Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest. 81:2001;1331-1338
52. Nielsen T.O., West R.B., Linn S.C., Alter O., Knowling M.A., O'Connell J.X., et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet. 359:2002;1301-1307